Immix Biopharma, Inc. IMMX Unrecognized share-based compensation costs for non-vested restricted stock awards, net of expected forfeitures
Unrecognized share-based compensation costs for non-vested restricted stock awards, net of expected forfeitures at other companies
Other financials
Where this comes from
Reported directly by Immix Biopharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions.
The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immix Biopharma, Inc.'s unrecognized share-based compensation costs for non-vested restricted stock awards, net of expected forfeitures.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immix Biopharma, Inc.'s unrecognized share-based compensation costs for non-vested restricted stock awards, net of expected forfeitures?
- Immix Biopharma, Inc. (IMMX) reported unrecognized share-based compensation costs for non-vested restricted stock awards, net of expected forfeitures of $3.98M in Q1 2026.
- How has Immix Biopharma, Inc.'s unrecognized share-based compensation costs for non-vested restricted stock awards, net of expected forfeitures changed year-over-year?
- Immix Biopharma, Inc.'s unrecognized share-based compensation costs for non-vested restricted stock awards, net of expected forfeitures increased by 66.4% year-over-year, from $2.39M to $3.98M.